Market Place
Sourcing Support
OnKure Announces Merger And $65 Million Private Placement
04 Oct 2024 //
GLOBENEWSWIRE
Reneo Shareholders Approve OnKure Merger
03 Oct 2024 //
GLOBENEWSWIRE
Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results
13 Aug 2024 //
GLOBENEWSWIRE
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
13 May 2024 //
GLOBENEWSWIRE
OnKure hitches Reneo’s ride to Nasdaq, with $65M PIPE to boot
13 May 2024 //
FIERCE BIOTECH
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
07 May 2024 //
GLOBENEWSWIRE
Reneo Reports Fourth Quarter And Full Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Reneo’s PhIIb rare disease trial failure forces layoffs, cost cuts
15 Dec 2023 //
ENDPTS
Reneo pulls plug on rare disease asset, sinking stock 87%
14 Dec 2023 //
FIERCE BIOTECH
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
02 Nov 2023 //
GLOBENEWSWIRE
Reneo Pharma Announces Poster Presentation at Upcoming Scientific Meetings
25 Oct 2023 //
GLOBENEWSWIRE
Reneo Pharma Announces Last Patient Last Visit in the Pivotal STRIDE Study
09 Oct 2023 //
GLOBENEWSWIRE
Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit
06 Oct 2023 //
GLOBENEWSWIRE
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
29 Aug 2023 //
GLOBENEWSWIRE
Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum
30 Jun 2023 //
GLOBENEWSWIRE
Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices
26 Jun 2023 //
GLOBENEWSWIRE
Reneo Pharma Announces Presentation and Posters at Mitochondrial Medicine
15 Jun 2023 //
GLOBENEWSWIRE
Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock
03 May 2023 //
GLOBENEWSWIRE
Reneo Announces Pricing of Public Offering of Common Stock
03 May 2023 //
GLOBENEWSWIRE
Reneo Reports Fourth Quarter and Full Year 2022 Financial Results
27 Mar 2023 //
GLOBENEWSWIRE
Reneo Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar
14 Mar 2023 //
GLOBENEWSWIRE
Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data
09 Mar 2023 //
GLOBENEWSWIRE
Reneo Pharma to Participate in SVB Securities Global Biopharma Conference
02 Feb 2023 //
GLOBENEWSWIRE
Reneo Receives Fast Track Designation from the FDA for Mavodelpar in LC-FAOD
31 Jan 2023 //
GLOBENEWSWIRE
Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences
03 Nov 2022 //
GLOBENEWSWIRE
Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences
06 Sep 2022 //
GLOBENEWSWIRE
Reneo Pharma Announces Poster Presentations at the International Network
29 Aug 2022 //
GLOBENEWSWIRE
Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors
02 Aug 2022 //
PRESS RELEASE
Reneo Pharmaceuticals Reports Positive Results from REN001 LC-FAOD Study
26 Jul 2022 //
GLOBENEWSWIRE
Reneo Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 Jul 2022 //
GLOBENEWSWIRE
Reneo Pharma to Present Data from PI REN001 Limb Immobilization Study
30 Jun 2022 //
GLOBENEWSWIRE
Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Reneo Pharma Reports Fourth Quarter and Full Year 2021 Financial Results
23 Mar 2022 //
GLOBENEWSWIRE
Reneo Pharma says Senior Leadership Promotions
07 Mar 2022 //
GLOBENEWSWIRE
Reneo Pharmaceuticals Reports Third Quarter 2021 Financial Results
11 Nov 2021 //
GLOBENEWSWIRE
Reneo Pharma Announces Notice of Allowance for Patent Application on REN001
14 Oct 2021 //
GLOBENEWSWIRE
Reneo Pharmaceuticals Hosting Key Opinion Leader Webinar on McArdle Disease
28 Sep 2021 //
GLOBENEWSWIRE
Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study
28 Jul 2021 //
GLOBENEWSWIRE
Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction
09 Jul 2021 //
GLOBENEWSWIRE
Reneo Pharma to Present at the Ladenburg Thalmann 2021 Healthcare Conference
07 Jul 2021 //
GLOBENEWSWIRE
Reneo Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
29 Jun 2021 //
GLOBENEWSWIRE
Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results
20 May 2021 //
GLOBENEWSWIRE
REN001 Granted Fast Track Designation by FDA for Patients with Primary
24 Mar 2021 //
GLOBENEWSWIRE
Novo and Abingworth back a $95M Series B for Reneo Pharmaceuticals
09 Dec 2020 //
ENDPTS
